Medline Industries Inc. (NYSE: MDLN) saw its shares decline 4.4% to $43.84 in premarket trading on Tuesday after a group of its principal investors announced a planned secondary offering totaling 75 million shares.
The block of shares up for sale was disclosed in an offering prospectus and is being placed by several major stockholders rather than by the company itself. The selling parties named in the filing are Blackstone Inc., Carlyle Group Inc., Hellman & Friedman and the Abu Dhabi Investment Authority.
Under the terms shown in the prospectus, Blackstone, Carlyle and Hellman & Friedman are each putting forward 23.3 million shares for sale, while the Abu Dhabi Investment Authority is offering about 5.1 million shares. The prospectus also reports that Medline has 1.31 billion shares outstanding.
Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are listed as global coordinators and joint bookrunning managers for the transaction, indicating wholesale distribution through major investment banking channels.
Medline, based in Northfield, Illinois, completed its initial public offering in New York last December; that public debut was the largest IPO of 2025, according to the prospectus language included with the offering notice.
The sale is structured as a secondary offering by existing shareholders. The market reaction in premarket trading was immediate, with the company's quoted share price moving lower on Tuesday morning following the announcement.
Because the offering is by selling stockholders and coordinated by major banks, it will be executed through the standard channels for a registered secondary sale. The prospectus provides the current outstanding share count but does not indicate company-issued primary shares or changes to Medline's capital structure beyond the sale of existing stockholder holdings.
Market participants and observers tracking supply of medical goods and the financing activities of large private-equity investors will likely follow the offering and any subsequent trading volatility. At this stage the filings show the stockholders involved, the share amounts being sold and the institutions managing the placement, but no additional operational or strategic details about Medline were disclosed in the prospectus referenced.